Sfoglia per AUTORE
BARTOLETTI M
Collezione AO Ordine Mauriziano

  

Items : 8

Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study. in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2024 Nov 4;79(11):2846-2853. doi: 10.1093/jac/dkae296.
2024
AO Ordine Mauriziano

Vena A; Schenone M; Corcione S; Giannella M; Pascale R; Giacobbe DR; Muccio M; Mornese Pinna S; Pari B; Giovannenze F; Geremia N; Mikulska M; Taddei E; Sangiorgi F; Bavaro DF; Scaglione V; Vassia V; Merli M; Bartoletti M; Viale P; De Rosa FG; Bassetti M;

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2024 Jul;35(7):667-676. doi: 10.1016/j.annonc.2024.04.007. Epub 2024 May 3.
2024
AO Ordine Mauriziano

Pignata S; Califano D; Lorusso D; Arenare L; Bartoletti M; De Giorgi U; Andreetta C; Pisano C; Scambia G; Lombardi D; Farolfi A; Cinieri S; Passarelli A; Salutari V; De Angelis C; Mignogna C; Priolo D; Capoluongo ED; Tamberi S; Scaglione GL; Arcangeli V; De Cecio R; Scognamiglio G; Greco F; Spina A; Turinetto M; Russo D; Carbone V; Casartelli C; et alii...

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. in Gynecologic oncology / Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23.
2023
AO Ordine Mauriziano

Musacchio L; Turinetto M; Arenare L; Bartoletti M; Califano D; Tuninetti V; Marchetti C; Cormio G; Loizzi V; Pisano C; Salutari V; Valabrega G; Priolo D; Cecere SC; Ventriglia J; Raspagliesi F; Perrone F; Fagotti A; Lorusso D; Scambia G; Pignata S;

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023.
2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G; Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; et alii...

Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023.
2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;

MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. in Cancer treatment reviews / Cancer Treat Rev. 2022 Nov;110:102458. doi: 10.1016/j.ctrv.2022.102458. Epub 2022 Aug 24.
2022
AO Ordine Mauriziano

Musacchio L; Valsecchi AA; Salutari V; Valabrega G; Camarda F; Tuninetti V; Giannone G; Bartoletti M; Marchetti C; Pignata S; Fagotti A; Scambia G; Di Maio M; Lorusso D;

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22). in British journal of cancer / Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22.
2022
AO Ordine Mauriziano

Musacchio L; Califano D; Bartoletti M; Arenare L; Lorusso D; Losito NS; Cormio G; Greggi S; Raspagliesi F; Valabrega G; Salutari V; Pisano C; Spina A; Russo D; Del Sesto M; Canzonieri V; Ferraù F; Zannoni GF; Loizzi V; Ghizzoni V; Casanova C; Tuninetti V; Ducceschi M; Del Vecchio V; Scalone S; Priolo D; Perrone F; Scambia G; Pignata S; et alii...

Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey. in Frontiers in oncology / Front Oncol. 2022 May 27;12:880008. doi: 10.3389/fonc.2022.880008. eCollection 2022.
2022
AO Ordine Mauriziano

Giannone G; Castaldo D; Tuninetti V; Scotto G; Turinetto M; Valsecchi AA; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;